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factors (P<.05). Using multivariate analysis, left ventricular hypertrophy
(LVH) was the strongest risk factor of HF (OR= 25.4, 95%CI=21-31), fol-
lowed by the presence of heart valve disease (OR=4.1, 95%CI=2.7-6.3), par-
oxystic or permanent atrial fibrillation (OR=4.05, 95%CI=3.1-5.3), renal
dysfunction, history of myocardial infarction and coronary artery disease
(OR<3 for each of them).
 
Conclusion:
 
 As suspected, LVH is the strongest risk factor for HF in
hypertension, while a majority of pts presented with > 3 risk factors for HF.
This study highlights the need for an early management of HF risk factors in
hypertensive pts. 
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We evaluated left ventricular remodeling (LVR) in patients (pts) with
heart failure (HF) of the 2 main aetiologies, coronary artery disease (CAD)
and dilated cardiomyopathy (DCM) after 1 year (y) of cardiac resynchroniza-
tion therapy (CRT). We enrolled 65 HF outpts with CRT indication (mean
age 67.5±13.2 ys 74.6% males, M): 33 had CAD-caused HF (70.2±6.7 ys,
84.4% M) and 32 DCM (64.6±17.3 ys, 64.5% M). All underwent ECG,
echocardiography, NYHA evaluation before and after 1 y of CRT. Before
CRT, NYHA was similar (CAD 2.7±0.7, DCM 2.7±0.8) and after 1 y it sig-
nificantly (p<0.05) and equally improved in both (CAD 2.3±0.5, DCM
2.2±0.7). Before CRT left ventricular ejection function (EF,%) was signifi-
cantly (p=0.04) less in DCM (22.9±7.7) than CAD (26.3±7.3) while end-dias-
tolic (EDV, ml) and end-systolic (ESV) volume, end-diastolic (EDD, mm)
and end-systolic (ESD) diameter were significantly greater in DCM than
CAD (EDV 239±78 vs 207±62 p=0.04, ESV 192±81 vs 152±57 p=0.03,
EDD 72.8±8.1 vs 68.8±8.6 p=0.05, ESD 59.5±10.7 vs 53.8±8.8 p=0.03).
After 1 y EF significantly improved in both (DCM 28.8±9.5 p=0.01, CAD
29.5±7.4 p=0.05) with a borderline trend to a greater increase in DCM. After
1 y EDV, ESV, EDD and ESD were reduced in both, with a significant reduc-
tion only in DCM. Expressing LVR as the volume parameters variation (
 
Δ
 
),
it was significantly greater in DCM than CAD: 
 
Δ
 
EDV DCM 44±72 vs CAD
20±34, p=0.04; 
 
Δ
 
ESV DCM 47±64 vs CAD 19±35, p=0.04. Before CRT
QRS duration (msec) was similar in both (DCM 172±33 CAD 176±28, p=ns)
as well as after (DCM 123±33 CAD 134±31, p=ns). Pre and post-CRT QRS
duration and 
 
Δ
 
QRS weren’t related to any modification of the above indi-
cated parameters, both in the overall population and the 2 groups. Thus, CRT
determines EF increase and LVR regression in both examined HF aetiologies.
Volume reduction is greater in DCM than CAD. No relation exists between
the volume and function parameters modifications and QRS duration both
before and after CRT. 
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Purpose:
 
 It remains unknown whether heart rate reduction by the I
 
f
 
 current
inhibitor ivabradine (IVA) improves left ventricular (LV) function of the inf-
arcted and reperfused myocardium. Accordingly, our goal was to investigate
the effect of IVA on global and regional LV function following myocardial
infarction and long term reperfusion in rabbits.
 
Methods:
 
 Myocardial systolic function was assessed before a 20 min cor-
onary artery occlusion and during the subsequent 3 weeks of reperfusion by
echocardiography and tissue tracking imaging. Throughout reperfusion, rabbits
received either IVA (10 mg/kg/day, n=9) or vehicle (Control, n=8) using
implanted osmotic pumps. At 3 weeks reperfusion, LV remodeling was inves-
tigated by histology and expression of several proteins (SERCA2a, RyR2-P,
phospholamban, FKBP12) involved in calcium handling.
 
Results:
 
 After 3 weeks, IVA induced a significant decrease in heart rate by
 
≈
 
20% as compared to Control (214±9 
 
vs
 
 266±14 bpm, respectively). In Con-
trol rabbits, ejection fraction and regional systolic displacement were signifi-
cantly decreased as compared to baseline values (43±4% vs 63±2% and
1.4±0.2 vs 2.8±0.2 mm, respectively) and were associated with LV enlarge-
ment and interstitial fibrosis within the reperfused zone (risk zone: 30±2% of
LV and infarct size: 8% of LV). Chronic administration of IVA prevented the
reduction in ejection fraction (58±3% vs 66±3% in baseline) and the decrease
in regional systolic displacement (1.9±0.3 vs 2.6±0.3 mm). This improvement
was not related to a difference in infarct size and interstitial fibrosis. Interest-
ingly, this was associated with a significant increase in FKBP12 expression in
the reperfused area without any changes in SERCA2a, RyR2-P and phospho-
lamban.
 
Conclusion:
 
 
 
Heart rate reduction with IVA significantly improves systolic
function after 3 weeks of reperfusion. This beneficial effect might result from
an adaptation of calcium handling as suggested by the increase in FKBP12
expression.
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The aim
 
 of the present work was to investigate changes in heart architec-
ture after chemical sympathetic denervation by 6OH-Dopamine (6OH-DA) in
mice.
Two months old mice (n=18) received 3 6OH-DA injections (200 mg/kg,
ip) or saline (n = 6) at 3 days of interval. 15 and 30 days after first injec-
tion, heart rate spectral variability (HRV, FFT) was analyzed in low frequency
(LF: 0.15-1.5 Hz) and high frequency (HF: 1.5-5 Hz) ranges and LH/HF ratio
was calculated. After sacrifice, blood was withdrawn for catecholamine deter-
mination (HPLC). Hearts were fixed (formaldehyde 10%) for histology or
frozen for western blot analysis (tyrosine hydroxylase, TH).
 
Results
 
 indicate that compared to controls (1410±145 pg/ml) plasma nore-
pinephrine levels were significantly lower at D15 (766±186 pg/ml) and D30
(675±288 pg/ml) after 6OH-DA without change in epinephrine. TH expression
was absent at D15 and significantly lower than in controls at D30. When com-
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pared to controls (48.5±6.2%), LF HRV was significantly reduced at D15
(31.6±5.4%) but not at D30 (58.2±16.2%) without change in HF. LF/HF ratio
was lower in 6OH-DA treated mice at D15 (0.5±0.1 vs 1.3±0.2 in controls)
but not at D30 (1.6±0.3). At D15, 6-OH-DA hearts exhibited mild structural
abnormalities with wavy cardiomyocyte appearance in septum. At D30, histo-
logical abnormalities were diffuse with myocytes intersecting at various angles
with bundles wavy appearance. Variability in cell size with anisocaryosis,
attenuated myocytes with perinuclear halo and shaped nuclei were observed.
No inflammation, interstitial fibrosis or necrosis was noticed.
 
In conclusion
 
, this study suggests that heart denervation induces myocardial
tissue disorganization. Relationship between these changes and sympathetic
nerve destruction and/or catecholamine depletion remains to be elucidated.
Apart from physiological significance, these results also bring new structural
basis to explain increased risk of cardiac disease during autonomic failure.
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Introduction:
 
 Latest generation continuous flow left ventricular assist
devices (LVADs) have been proposed as an alternative to heart transplantation
for end-stage heart failure. However, postoperative right ventricle (RV) dys-
function remains common and has a negative impact on prognosis. Purpose of
our study was to identify echocardiographic or hemodynamic parameters that
could predict early RV failure after LVAD implantation in patients with biven-
tricular dysfunction.
 
Methods:
 
 Fourteen patients with biventricular dysfunction who have been
evaluated for LVAD implantation were included. Right and left ventricular dys-
function were respectively defined as: tricuspid annular plane excursion < 16 mm
(TAPSE) and LV ejection fraction < 35%. In all patients, preoperative measure-
ments were obtained at rest. In 7 patients, right heart catheterization was per-
formed simultaneously with increasing doses of dobutamine (15
 
γ
 
/Kg/min).
Primary endpoint was death caused by right ventricle systolic dysfunction or need
for right ventricle mechanical support within 30 days after surgery (RVSD+).
 
Results:
 
 Mean recipient age was 58±7 years. Primary end-point (RVSD+)
was noted in five patients. Preoperative demographic, echocardiographic and
hemodynamic data were similar between RVSD+ and RVSD- patients (Table).
Percent increase of TAPSE and systolic PAP between basal and high dob-
utamine dose was significantly lower in RVSD+ than in RVSD- patients.
 
Conclusion:
 
 Percent increase of TAPSE and systolic PAP induced by high
dose dobutamine infusion might be two interesting criteria to assess RV con-
tractile reserve and predict RV outcome after LVAD implantation in patient
with biventricular dysfunction.
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Rationale:
 
 Heart failure (HF) with preserved LVEF has been individual-
ized in the recent years as a specific entity, with different mechanisms, special
baseline characteristics, a poor prognosis and no clearly recognized treatment.
Recent papers have focused on patients with LVEF between 40% and 50%
who could not be clearly classified as patients with reduced or preserved
LVEF. 
 
Objectives:
 
 to describe the management care of patients according to
the LVEF with special emphasis on patients belonging to the "grey zone".
 
Methods:
 
 Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with HF
and have been hospitalised for HF within the previous 18 months. Patients are
classified according to the LVEF at hospital discharge. 
 
Results:
 
 412 French
outhospital cardiologists included 1 452 patients meeting the inclusion criteria.
Management care at hospital discharge according to LVEF (known in 1 408
patients) is detailed below.
 
Conclusion:
 
 This is the first French survey in patients managed by cardi-
ologists after hospital discharge for HF. Cardiologists mainly care for patients
with low LVEF. Treatment at hospital discharge is optimal regarding medical
classes, with poor differences according to EF. Rate of betablockers and ACEI
is quite high in the group with EF > 50%, even if it is lower than in the groups
with low EF. As a whole, in France, the 40-50% group is managed as the <
40% one.
 
Table. Drug therapy according to LVEF 
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Background:
 
 Alterations of diffusion lung carbon monoxide (DLco) and
alveolar-capillary membrane gas conduction (Dm) are associated with poor
prognosis in patients with heart failure (HF) or stable coronary artery disease
(CAD) even when LV systolic function is preserved. However, the impact of
LV function on diffusing lung capacity is poorly understood.
 
Methods and Results:
 
 Twelve healthy subjects were compared to 19
patients with stable HF and LV systolic dysfunction and to 12 patients with
stable CAD and preserved LV systolic function. Diffusing lung capacity was
assessed by DLco and Dm, using single breath technique and Roughton-For-
 
 
Baseline Measurement 
(n=14)
Change after 
Dobutamine infusion,% 
(n=7)
 RVSD- RVSD+ p RVSD- RVSD+ p
N
 
9 5  3 4  
 
TAPSE, mm
 
14 ± 2 14 ± 2 0.9 55 ± 5 26 ± 2 0.03
 
Systolic PAP, 
mmHg
 
51 ± 7 53 ± 6 0.8 42 ± 8 4 ± 7 0.05
 
Cardiac Output, 
l/min
 
3.3 ± 0.5 3.5 ± 0.5 0.9 87 ± 10 93 ± 47 0.7
 
Pulm Vasc Res, 
Wood
 
3.9 ± 1 4.3 ± 1 0.6 2 ± 41 -36 ± 7 0.8
 
 LVEF<40% 
n=792
LVEF 40-50% 
n=366
LVEF>50% 
n=250 p
ACEI/ARB
 
91% 90%† 83% 0,002
 
Betablocker
 
78% 76%† 64% <0,0001
 
Loop diuretics
 
90% 83%* 82% <0,001
 
Spironolactone
 
29% 19%* 21% 0,0003
 
Digoxin 
 
16% 15% 21% 0,15
 
Calcium antagonists
 
9% 18%†* 27% <0,0001
 
Anticoagulants
 
43% 41% 43% 0,64
 
p by ANOVA with Bonferroni correction; 
† p<0.05 for comparisons between “grey zone” and LVEF>50%; 
* p<0.05 for comparisons between “grey zone” and LVEF<40%. 
